Among adults with nonalcoholic fatty liver disease (NAFLD), 25% of deaths are attributable to cardiovascular disease (CVD). CVD risk reduction in NAFLD requires not only modifi cation of traditional CVD risk factors but identifi cation of risk factors unique to NAFLD.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the United States, aff ecting an estimated 80 million adults ( 1 ) . Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD and can lead to the development of cirrhosis and hepatocellular carcinoma (2) (3) (4) (5) . Although liverrelated complications are frequent among those with NAFLD, cardiovascular disease (CVD) is the most common cause of mortality, accounting for 25% of deaths ( 6 ) . NAFLD is associated with an increased prevalence of aortic and coronary atherosclerosis, high-risk coronary plaques, and increased coronary artery calcium scores. Further, NAFLD is associated with increased fatal and non-fatal CVD events including acute coronary syndromes (7) (8) (9) .
Th e identifi cation of CVD risk factors among the general population has been the focus of considerable investigation. Identifying which patient characteristics confer an increased risk of CVD has contributed to the understanding of CVD pathophysiology. Unlike in the general population, little attention has been focused on elucidating non-traditional CVD risk factors in NAFLD. A single study evaluated the Framingham Risk Score, a composite score of traditional risk factors including age, gender, cholesterol, highdensity lipoprotein (HDL) level, smoking status, and hypertension, as a CVD predictor in NAFLD ( 10 ) . Although the Framingham
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Risk Score accurately predicted a 10-year CVD risk, none of its individual components were found to be predictors of CVD, and no novel risk factors were evaluated. Th us, little is known about the value of non-traditional CVD risk factors in NAFLD.
CVD events are believed to be rare in individuals with chronic and end-stage liver disease ( 11 ) . Th e systemic vasodilatation and decreased lipid synthesis that accompany liver disease are thought to decrease CVD risk ( 12, 13 ) . However, NAFLD is, in many ways, distinct from other causes of liver disease. Even in late stages, NAFLD is associated with dyslipidemia and hypertension, which confer increased CVD risk ( 14 ) . We hypothesize that the same drivers of progressive NAFLD, systemic infl ammation, lipid oxidation, and endothelial dysfunction, may also drive the development of CVD, making CVD increasingly prevalent as NAFLD progresses and associated with markers of liver disease progression. By using a large electronic medical record (EMR)-based cohort of 8,409 individuals with NAFLD, we evaluated those with and without CVD to identify unique CVD risk factors.
METHODS
Patients and data for the present study were drawn from a previously described cohort created from the Partners HealthCare EMR utilizing the Partners Research Patient Data Registry (RPDR). Th is centralized clinical data registry contains data from all institutions in the Partners HealthCare System and includes data on ~10 million patients with ~2.3 billion EMR facts. We utilized data from the Massachusetts General Hospital and Brigham and Women's Hospital, both in Boston, that serve the greater Northeast United States.
NAFLD was defi ned using a previously validated algorithm for the identifi cation of NAFLD in an EMR database ( 15 ) . Th e algorithm calculates a NAFLD probability per patient based on the most recent triglycerides measurement, the total number of billing codes for NAFLD (ICD-9 571.8 or 571.9), and the total number of mentions of NAFLD in clinical narrative notes. Th e algorithm incorporates text processing to identify clinical narrative notes associated with NAFLD. As a fi rst step, the algorithm was applied to the RPDR cohort to identify all individuals with NAFLD. As a second step, patients with either a diagnosis of cirrhosis or a nonviral hepatitis were excluded. In total, 8,409 adults aged ≥18 years exceeded the NAFLD probability threshold of 0.85 and were considered in our analysis.
CVD was considered present when an individual had ≥1 ICD-9 or CPT code for myocardial infarction, CVD, ischemic heart disease, angina, or peripheral vascular disease. Comorbidities were determined by ≥1 ICD-9 or CPT code for the comorbidity over their lifetime prior to the diagnosis of CVD. We extracted from the notes expressions to determine an individual's most recent smoking status (past, present, never). In addition, to determine whether the patient had a family history of CVD, we identifi ed in clinical narrative notes the indication of at least one family member being reported as having myocardial infarction, heart attack, angina, coronary artery bypass surgery, cardiovascular percutaneous intervention, or sudden death. For laboratory variables, when more than one value was present the average of all available values was used.
NAFLD fi brosis score (NFS) was calculated according to the published formula ( 16 ):
Model for End-Stage Liver Disease (MELD) score was calculated according to the published formula ( 17 ):
Statistical analysis
Categorical variables were compared using the χ 2 -test. Continuous variables were compared using the t -test or the Mann-Whitney's test, as appropriate. To determine odds ratio (OR) for the variables associated with the presence of NAFLD, logistic regression was performed. Th e following variables, based on statistical signifi cance and clinical relevance, were included: age, gender, ethnicity, diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-HDL cholesterol, renal failure, low-density lipoprotein level (LDL), alanine aminotransferase level, NFS, MELD score, and family history of CVD. Statistical analysis was performed on SAS 9.4 (SAS Institute, Cary, NC). We examined the collinearity among covariates in the multivariable model based on their variance infl ation factor. Th e multivariable model consists of covariates that do not have overly high variance infl ation factor (maximum VIF 3.3). Th is study was approved by the Partners Healthcare Human Research Committee that serves as the institutional review board for both Brigham and Women's Hospital and Massachusetts General Hospital.
RESULTS

Baseline characteristics
Of the 8,409 individuals, 3,243 individuals had CVD, whereas 5,166 individuals had no evidence of CVD ( Table 1 ) . Individuals with NAFLD and CVD were older (61.9 vs. 52.3 years, P <0.0001), more likely to be male (55.2 vs. 51.3%, P =0.0006), and Caucasian (92.6 vs. 87.1%, P <0.0001). Th ere was no diff erence in the mean BMI or prevalence of obesity between groups (33.3 vs. 33.4 kg/ m 2 , P =0.30). All variables considered were calculated based on the available values or measurements from date of birth of a patient to the last EMR fact that was available in the cohort-i.e., September 2010.
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Traditional CVD risk factors
Traditional risk factors for CVD were more prevalent in individuals with NAFLD and CVD compared with those with NAFLD alone on univariate analysis ( Figure 1 ). Type 2 diabetes (82.0 vs. 64.7%, P <0.0001) was more frequent and median HbA1C (7.3 vs. 7.08%, P =0.0009) was signifi cantly higher in those with both CVD and NAFLD compared with those with NAFLD alone. Hypertension (84.6 vs. 57.0%, P <0.0001), family history of CVD (67.0 vs. 58.3%, P <0.0001), and current or past tobacco use (53.7 vs. 41.1%, P <0.0001) were associated with the presence of CVD in NAFLD patients. Other comorbidities including obstructive sleep apnea, anxiety and depression, chronic obstructive pulmonary disease, and asthma were more frequent in NAFLD and CVD when compared with NAFLD alone ( Figure 1 ).
Dyslipidemia and statin use were more frequent in individuals with both NAFLD and CVD than those with NAFLD alone (75.4 vs. 55.5%, P <0.0001 and 49.0 vs. 26.1%, P <0.0001, respectively). Mean LDL (106.3 vs. 112.5 mg/dl, P <0.0001), total cholesterol (214.5 vs. 221.9 mg/dl, P <0.0001), and non-HDL cholesterol (182.3 vs. 189.7 mg/dl, P <0.0001) were lower in those with NAFLD and CVD compared with those with NAFLD alone ( Figure 2a ) . HDL levels were lower in those with CVD (35.9 vs. 37.9 mg/dl, P <0.0001), although there was no diff erence in triglyceride levels. Other risk markers of CVD disease including ESR (40.7 vs. 33.2 mm/h, P <0.0001) and C-reactive protein (37.3 vs. 32.9 mg/l, P =0.007) were higher in those with CVD and NAFLD ( Figure 2b and Figure 3 ) .
A diagnosis of renal failure was more common in CVD and NAFLD compared with those with only NAFLD (16.8 vs. 7.0%, P <0.0001). Individuals with CVD and NAFLD had higher serum 
Non-traditional risk factors for CVD
Several non-traditional risk factors for CVD and NAFLD were identifi ed on univariate analysis. CVD was associated with decreased albumin levels (3.7 vs. 3.9 g/dl, P <0.0001) and platelet counts (246.1 vs. 259.6 th/cumm, P <0.0001) compared with those with NAFLD alone. In addition, patients with NAFLD and CVD had increased total bilirubin (0.8 vs. 0.7 mg/dl, P <0.0001) and INR (1.4 vs. 1.2, P <0.0001). NFSs (2.1±1.52 vs. 1.3±1.45, P <0.0001) and mean MELD scores (12.3±5.7 vs. 10.2±5.0, P <0.0001) were also signi fi cantly higher in those with both CVD and NAFLD compared with those with NAFLD alone. No diff erence was seen in mean AST levels between groups, although those without CVD had slightly increased alanine aminotransferase level (45.8 vs. 45.5 U/l, P <0.0001) when compared with those with CVD.
Factors associated with CVD on regression analysis
On multivariable analysis aft er controlling for gender, ethnicity, diabetes, dyslipidemia, alanine aminotransferase, and obstructive sleep apnea, family history of CVD and hypertension were most strongly associated with the presence of CVD ( Table 2 ). Age, non-HDL cholesterol, and renal failure remained directly associated with the presence of CVD. LDL was inversely associated with the presence of CVD. We assessed the correlation between LDL level and use of lipid lowering medication. Lipid lowering medication use was inversely correlated with the LDL level ( r =−0.09, P <0.0001), indicating that statin use was likely associated with CVD.
In addition, the non-traditional CVD risk factors MELD score, albumin level, and sodium level were associated with increased risk of CVD. MELD score was associated with an increased risk of CVD aft er adjustment with an OR 1.10, 95% confi dence interval (CI) 1.06-1.14. Albumin and sodium levels were inversely associated with risk of CVD, demonstrating that low albumin and sodium levels confer an increased risk of CVD (OR 0.52, 95% CI 0.44-0.63 and OR 0.96, 95% CI 0.93-0.99, respectively).
CVD by NFS
Histologic diagnosis of NASH was not available in the present cohort. To evaluate whether CVD prevalence diff ered in those with NASH and advanced fi brosis, we evaluated the CVD prevalence by the NFS. Individuals with NAFLD and a NFS>0.676 had a signifi cantly higher prevalence of CVD compared with those with NFS≤0.676 (39 vs. 20%, P <0.0001). Th is fi nding further suggests an association between advanced fi brosis and CVD.
DISCUSSION
Th e present study demonstrates that among individuals with NAFLD, MELD score, albumin, and sodium are non-traditional predictors of CVD. Further, we confi rm the validity of our model by demonstrating that several known risk factors for CVD in the general population are associated with CVD in NAFLD.
We found that MELD score, albumin, and sodium levels were associated with a diagnosis of CVD. Each of these factors is known to be independently associated with disease progression in chronic liver disease (18) (19) (20) (21) (22) (23) (24) (25) (26) . Further, we demonstrated that those with advanced fi brosis as predicted by NFS had a higher prevalence of CVD, also suggesting that advanced liver disease is associated with increased risk of CVD. Our fi ndings demonstrate that CVD may be associated with progressive liver disease among those with NAFLD and suggest that similar processes may drive the development of atherosclerosis, steatohepatitis, and liver fi brosis. Th is fi nding is counter to the widely held belief that CVD events are less frequent in end-stage liver disease in part due to systemic vasodilatation and impaired lipid synthesis ( 11 ) . However, NAFLD may likely be an exception to this rule secondary to the associated systemic infl ammatory response, endothelial dysfunction, and lipid peroxidation that accompanies advanced NAFLD histology and can impact the development of atherosclerotic disease (27) (28) (29) (30) . Furthermore, hypercoagulablity and impaired fi brinolysis found in NASH may also contribute to CVD progression ( 31, 32 ) . Th is fi nding has several important implications. First, a relationship between worsening liver disease and CVD suggests that individuals with advanced liver disease from NAFLD and those being evaluated for liver transplantation should undergo rigorous evaluation of CVD and CVD risk management. In addition, this fi nding further strengthens the link between NAFLD and CVD and suggests that treatment of one condition could positively impact the other.
In the present study, we confi rm that traditional CVD risk factors including age, family history, hypertension, and renal failure are risk factors for CVD in NAFLD. Th ese fi ndings demonstrate the ability of our algorithm ( 15 ) and the cohort that we created to accurately identify CVD and comorbidities. Family history of CVD was most strongly associated with CVD in individuals with NAFLD (OR 4.25, 95% CI 1.84-9.83), a previously unreported fi nding. Family history of CVD in the general population is a predictor of CVD-related death in men and women but has not been evaluated in a NAFLD population (33) (34) (35) . Th is association suggests that a genetic component to CVD risk in NAFLD patients may exist, and further evaluation is needed in a prospective cohort. Traditional risk factors of age, renal failure, and hypertension were also associated with CVD in NAFLD ( 36 ) .
Th e LDL level is a known risk factor for the development of CVD. However, in the present study, LDL was inversely associated with CVD (OR 0.99, 95% CI 0.98-0.99). Although the inverse relationship between LDL and CVD prevalence in NAFLD may seem to contradict data in non-NAFLD cohorts, we believe that this fi nding is due to the signifi cantly higher frequency of lipid lowering medication use in those with CVD compared with those with NAFLD alone (49.0 vs. 26.1%, P <0.0001).
Our study has several important limitations. Th e cross-sectional design of our study allows for assessment of factors associated with the presence of CVD in NAFLD but does not allow us to comment on causality of those risk factors in the pathogenesis of CVD in NAFLD. However, it does allow for the identifi cation of several novel CVD-associated variables that can be further assessed in prospective cohorts. Our study also uses a validated algorithm to identify NAFLD, but liver histology was not available to diff erentiate between steatosis and NASH or to determine fi brosis stage. To address this, NFSs, which serve as a proxy for the presence of NASH and advanced fi brosis, were calculated ( 16 ) . Our study assessed MELD scores in a population that was not confi ned to those with cirrhosis. As a result, other causes of an elevated MELD score (e.g., anti-coagulation leading to an increased INR) are possible. However, the MELD has been demonstrated to have predictive value outside of a cirrhotic population and in our study was accompanied by positive correlations between CVD and other markers of liver disease including albumin and platelet count ( 19, 37 ) . In addition, comorbidities in our study were defi ned by the presence of one or more diagnostic codes of that condition. Further, patients with CVD may more frequently attend medical appointments, have more frequent laboratory tests, and may confound our results.
